BIOTECH ASSISTANT / FIELD NOTES

Sunshine Guojian outlines oral IL-23 program 629 and weekly-dosing research goal

Company / institutional announcement · Sunshine Guojian / original IR record

Source published: 2026-04-03

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Sunshine Guojian discussed its 629 oral IL-23 cyclic peptide program in an investor-relations record, saying pharmacokinetic findings suggest potential for weekly dosing. The document did not provide study species, participant details, quantitative exposure, or clinical outcomes. These are company development claims and do not establish validated human bioavailability, weekly clinical efficacy, or an approved dosing regimen.

Why it may matter

Adds an early autoimmune oral-peptide competitor; comparisons of duration require study design, species, exposure, and human evidence.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Oral cyclic peptides

Follow the evidence

Companies mentionedSunshine Guojian ↗

Explore field companies →Explore literature →

Related updates

2026-11-07Johnson & Johnson (PR Newswire)

Icotrokinra meets Phase 3 joint-response endpoint in biologic-naive psoriatic arthritis

Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.

Companies mentionedJohnson & Johnson ↗

Oral cyclic peptides Ask AI ↗

2026-11-06Entera Bio investor filing

Adjacent oral-peptide field: Entera reports $265.9 million cash as EB613 Phase 3 preparations continue

Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.

Oral cyclic peptides Ask AI ↗

2026-11-06Johnson & Johnson

ICONIC-ASCEND reports icotrokinra noninferiority to ustekinumab in plaque psoriasis

Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.

Companies mentionedJohnson & Johnson ↗

Oral cyclic peptides Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗